BioSpace News Archive

Stereotaxis today reported financial results for the second quarter ended June 30, 2021.

CytoAgents, Inc., a clinical stage biotechnology company, announced today that its lead drug candidate, GP1681, has successfully completed Phase 1 clinical trials with a strong safety profile. Building on these positive results, the company also announced the close and oversubscription of an initial equity round and is now positioned to raise a larger Series A round in early 2022 to enable two Phase II trials.

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its second quarter 2021 financial results and provides a business update.

Sydnexis, Inc. announced the completion of a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.

Tesis Labs, a leader in targeted genetic sequencing, and Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a new collaboration to maximize the power of genetic sequencing and bioinformatics.

Athersys, Inc. (NASDAQ: ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has completed enrollment in its TREASURE study in Japan, evaluating MultiStem® (invimestrocel) cell therapy treatment in patients who have suffered an ischemic stroke.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on recently issued patents for the use of Adial’s lead asset, AD04, for the treatment of both Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD).

CARD9 deficiency is a type of immune system disorder. It is triggered due to a gene mutation called as caspase recruitment domain family member 9.

The “Global Dry Eye Treatment Device Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis.

CorEvitas, LLC, the leading sponsor of registries in autoimmune and inflammatory diseases announces first patient enrollment in a new biospecimen study for patients enrolled in its rheumatology registries.